Patients suffering from inflammatory and autoimmune diseases are usually treated with drugs possessing IKK-β inhibitory effects, such as the ATP-competitive IKK-β inhibitor, sulfasalazin [44] or Cys-179-targeting compounds including xanthohumol [45] and TPCK [46]. The gene discussed is IKBKB; the disease is autoimmune disease.